Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study
- HERIZON-BTC-01 study group
- Memorial Sloan-Kettering Cancer Center
- Zhongshan Hospital
- Seoul National University
- Yonsei University
- University of Ulsan
- Huazhong University of Science and Technology
- Vall d'Hebron Institute of Oncology
- Naval Medical University
- CHU de Brest
- Zhejiang Cancer Hospital
- University College London
- The Catholic University of Korea
- AdventHealth
- Oregon Health and Science University
- Pusan National University
- Imperial College Healthcare NHS Trust
- Gustave Roussy
- BeiGene
- Zymeworks, Inc.
- University of Texas MD Anderson Cancer Center
Research output: Contribution to journal › Article › peer-review
275
Link opens in a new tab
Scopus
citations